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Background: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of
death worldwide and, according to the World Health Organization, its prevalence will double
by 2020. COPD is a chronic inflammatory disease of the lung characterized by poorly reversible
airflow limitation and, frequently, by extrapulmonary manifestations. In particular, the cardio-
vascular manifestations are responsible for high morbidity and mortality.
Methods and results: A systematic literature search was performed of studies published in
Medline until December 2010, using the key-words: COPD, bacterial colonization, COPD exac-
erbation, atherosclerosis, systemic inflammation, cardiovascular event and risk factors. In
addition to the studies identified in the primary search, reference lists of included articles
were analyzed for additional papers related to the topic.
The pathogenetic mechanisms underlying atherosclerosis e namely inflammation, oxidative
stress and endothelial dysfunction e are in common with COPD. Moreover, they are increased
in the presence of COPD, especially in patients who present airway bacterial colonization,
increased rate of exacerbations and elevated levels of both airway and systemic inflammation.
Conclusion: COPD is associated with an increased burden of atherosclerotic disease. Systemic
inflammationandoxidative stress playkey roles in this association.COPDpatientswithairwaybacte-
rial colonization, as compared to patients without airway colonization, generally present more
frequent exacerbations and higher levels of both airway and systemic inflammation. This COPD
subgroup should be considered at particularly increased risk of developing cardiovascular complica-
tions and receive more attention concerning diagnosis, treatment, prevention and research.
ª 2012 Elsevier Ltd. All rights reserved.24909353; fax: þ39 0824909614.
@fsm.it (S. Fuschillo).
2 Elsevier Ltd. All rights reserved.
Contents916 S. Fuschillo et al.Figur
chara
for anIntroduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 916
Cardiovascular morbidity and mortality associated with COPD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 917
Inflammatory pathways in COPD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 917
Inflammatory pathways in atherosclerosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 918
Airway bacterial colonization, exacerbation frequency, and systemic inflammation in COPD . . . . . . . . . . . . . . . 919
Conclusive remarks and future research prospects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 920
Conflict of interest statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 921
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 921Introduction
Chronic obstructive pulmonary disease (COPD) affects over
5% of adult population in Western countries and accounts
for approximately 750,000 hospitalizations every year in
the United States,1 with an economic burden of 24 billion
dollars.2 Moreover, its prevalence and mortality is pro-
jected to rise continuously, and the World Health Organi-
zation predicts that COPD will become by 2020 the third
leading cause of death (currently fourth) and the fifth
leading cause of disability (currently twelfth), worldwide.3
COPD is a chronic inflammatory disease of the lung char-
acterized by the presence of poorly reversible and generally
progressive airflow limitation.4 In over 80% of cases, ciga-
rette smoking is considered to be the causative factor.5,6
The clinical picture of COPD is frequently complicated
by extrapulmonary manifestations,7 such as skeletal muscle
dysfunction and wasting,8 osteoporosis9 and atheroscle-
rosis.10 These manifestations are thought to be due to the
spreading of the inflammatory response from the lung into
the systemic circulation,11e14 with possible involvement of
various organs.
The clinical course of COPD is punctuated by recurrent
episodes of acute-subacute increase in both airway and
systemic inflammation (Fig. 1), as well as in respiratory
symptoms, otherwise known as exacerbations.15 Exacerba-
tions have a major negative impact on the patient’s quality
of life, and contribute significantly to the accelerated
decline in lung function typically observed in COPD.16e19
Exacerbations are caused mainly by bacteria and
viruses,20 but various predisposing factors appear to play
a role, including airway bacterial colonization.20,21
Compared to patients whose airways are not colonized,
COPD patients with airway bacterial colonization presentCigarette smoking 
Environmental 
pollutants 
COPD 
Exacerbat
Stable p
e 1 Cigarette smoking and/or environmental pollutants c
cterized by chronic airway inflammation and low grade system
increase in both airway and systemic inflammation.more frequent exacerbations, and a higher level of airway
inflammation both in the stable state and during exacer-
bations.22e24 Moreover, in some studies bacterial coloniza-
tion of the airways has been associated also with systemic
inflammation both in the stable state25 and during exacer-
bations.26 In this context, an association between sputum
purulence and increased serum C-reactive protein (CRP)
levels during an exacerbation of COPD has also been
described in another study.27 Taken together, these obser-
vations suggest that there may be a relationship between
airway bacterial colonization and systemic inflammatory
responses.26,28e30
Although respiratory failure is a common endpoint in
advanced COPD, patients die more frequently from
cardiovascular events, such as coronary disease, arrhyth-
mias, stroke, and sudden death, as well as from lung
cancer, rather than from respiratory failure.5 Accordingly,
the risk for cardiovascular disease is markedly increased in
patients with COPD,31 and poor lung function has been
shown in these patients to be a powerful predictor of
cardiovascular risk, even after adjusting for established
cardiovascular risk factors.32 In particular, in the large Lung
Health Study, Anthonisen and coworkers report that for
every 10% decrease in forced expiratory volume in 1 s
(FEV1) there is an increase of 14% in all-cause mortality, of
28% in cardiovascular mortality, and of almost 20% in non-
fatal coronary events.33 It is worth noting that in this
study adjustments were made for the most relevant
confounders, such as age, sex, smoking, cholesterol, social
class, and educational level.33
The mechanisms by which the pulmonary changes
observed in COPD can lead to increased cardiovascular
morbidity and mortality are still poorly understood.
However, inflammatory pathways have recently emerged ased phase 
hase Chronic  airway inflammation and low 
grade systemic  inflammation 
Acute increase in both airways and 
systemic inflammation 
ause COPD in predisposed subjects. COPD in stable phase is
ic inflammation. Acute exacerbations of COPD are responsible
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rosis.34 On the other hand, as outlined above, also COPD is
now considered to be an inflammatory disease in which
both pulmonary and systemic inflammation appear to have
a role. Systemic inflammation could then constitute the link
between COPD and respiratory symptoms, on the one hand,
and atherosclerosis and increased cardiovascular risk, on
the other.
The present review will begin with a brief outline of the
current epidemiological and clinical evidence on the
cardiovascular morbidity and mortality associated with
COPD. After a summary of the inflammatory pathways
involved in both COPD and atherosclerosis, it will then
discuss the possible relationship between airway bacterial
colonization, exacerbation frequency, and systemic
inflammation in COPD. It will conclude with an overview of
the prospects for future research.Cardiovascular morbidity and mortality
associated with COPD
The existence of an association between COPD and
cardiovascular morbidity and mortality is supported by both
epidemiological and prospective clinical studies.
In the Third National Health and Nutrition Examination
Survey Epidemiologic Follow-up Study, a cohort of 1861
subjects, aged 40e60 years, was followed and cardiovas-
cular mortality assessed. Individuals in the lowest FEV1
quintile had the highest risk of cardiovascular mortality
(relative risk 3.36; 95% confidence interval 1.54e7.34), with
a fivefold increase in the risk, in comparison to individuals in
the highest FEV1 quintile.
32 In the large Tucson Epidemio-
logical Study of Airways Obstructive Disease,35 a cardiovas-
cular event was reported on the death certificate as the
primary cause of death in as many as 42% of patients who
presented COPD as a contributing cause. In the Lung Health
Study,33 examining the causes of death and hospitalization in
5887 patients with mild to moderate COPD over a period of
five years, all-cause mortality resulted to be 2.5%, and, of
this, 25% was due to cardiovascular events.
In a population-based cohort of 5648 patients with
COPD, as compared to the general population, Huiart and
colleagues found significantly higher rates of cardiovascular
morbidity and mortality.36 In the Towards a Revolution in
COPD Health trial, involving more than 6000 COPD patients
randomized to receive either a combination of salmeterol/
fluticasone propionate, its monotherapy components, or
placebo for 3 years, mortality was ascribed to respiratory
complications, cardiovascular events, and cancer in 36%,
27%, and 22% of cases, respectively.37 In population-based
studies, several groups evaluated the relationship between
FEV1 and cardiovascular mortality, and reported results
similar to those cited above.38e40
Cardiovascular risk appears also to be increased in
subjects with chronic bronchitis. In a 13-year follow-up
study involving 19,444 randomly selected eastern Finnish
subjects of both gender, men with cough and phlegm were
reported to have an elevated risk of dying from cardiovas-
cular disease independently of the major cardiovascular
risk factors.41 In the Multifactor Primary Prevention Trial
conducted in Sweden,42 individuals with daily cough andsputum production presented an age-adjusted 42% increase
in the risk of cardiovascular mortality compared to indi-
viduals without respiratory symptoms.Inflammatory pathways in COPD
A chronic inflammatory response, with accumulation of
neutrophils, macrophages, and cytotoxic T-lymphocytes,
and release of a number of chemical mediators is a char-
acteristic feature of COPD. The inflammatory process
induces the activation of elastolytic enzymes and metal-
loproteinases that are responsible for the emphysematous
and airway remodelling changes observed in COPD.43
COPD has also been associated to pulmonary and
systemic oxidative stress, both in the stable state and
during exacerbations.44,45 In this regard, peripheral blood
neutrophils harvested from patients with COPD, as
compared to neutrophils from normal subjects, produce
more reactive oxygen species (ROS).46 This increased
oxidative stress may be the result of either the large burden
of activated inflammatory cells present in the lower
airways, or of the reduced antioxidant capacity of the lung,
or a combination of the two.47
In general, oxidative stress seems to play an important role
in amplifying the inflammatory process, due to the activation
of oxidant-sensitive transcriptional factors that lead to an
increased transcription of pro-inflammatory genes.47 In
particular, in COPD the excessive ROS production, especially
during exacerbations, has a detrimental effect on the cellular
components and biomolecules (lipids, proteins, nucleic
acids), and contributes to endothelial dysfunction.48e50
Among the various intracellular ROS, superoxide anion
appears to be particularly important in that it inactivates
nitric oxide by transforming it into peroxynitrite,51 so
abolishing its numerous anti-inflammatory actions such as
inhibition of leukocyte adhesion to endothelium, inhibition
of platelet aggregation, reduction in the tone and prolif-
eration of smooth muscle cells, alteration of lipoprotein
metabolism, and activation of the antioxidative superoxide
dismutase enzyme system.52,53
Moreover, superoxide anion causes endothelial dysfunc-
tion, that further amplifies the inflammatory response.51 In
this regard, Barr et al. observed a significant relationship
between some indexes of endothelial dysfunction on the one
hand, and severity of airway obstruction, severity of
emphysema, and some markers of systemic inflammation,
e.g. CRP and leukocyte count, on the other.54 In another
study it has been reported that both endothelium-
dependent and endothelium-independent vasodilatation is
significantly impaired in patients with stable COPD.55
As anticipated above, increased systemic inflammation
in association with airway bacterial colonization has been
observed in patients with stable COPD. However, whether
bacterial colonization is able to drive endothelial dysfunc-
tion is an important point that, unfortunately, has not yet
been adequately addressed in the literature.
Conversely, it has been reported that endothelial
dysfunction increases during an acute exacerbation of COPD,
and improves as the exacerbation recedes.56 The authors
suggest that the exacerbation induced enhancement of
systemic inflammation and, in particular, the increased
918 S. Fuschillo et al.concentration of CRP may contribute to the observed
increase in endothelial dysfunction during exacerbations.56
Accordingly, CRP has been shown to present a number of
actions that may significantly impair endothelial func-
tion.57,58 Of note, CRP potently down-regulates endothelial
nitric oxide synthase (eNOS) transcription and destabilizes
eNOS mRNA, with consequent decreases in both basal and
stimulated NO release.59
One of the consequences of endothelial dysfunction,
namely arterial stiffness, that can be measured by aortic
pulse wave velocity, results to be increased in patients with
COPD, as compared to non-COPD subjects matched for
a number of cardiovascular risk factors.60 Arterial stiffness is
furthermore higher in patients with severe to very severe
COPD compared to those with mild to moderate disease.61
Indeed, McAllister and coworkers found that both FEV1 and
computerized scan based emphysema severity are the most
powerful predictors of arterial stiffness in COPD patients,
suggesting the existence of common pathogenetic features
between chronic obstruction of the lung and systemic
vascular dysfunction.61 Finally, both in patients with COPD
and in healthy subjects, arterial stiffness has been shown to
correlate with markers of systemic inflammation, such as
interleukin (IL)-6 and CRP serum levels.31,60,62Inflammatory pathways in atherosclerosis
Similarly to COPD, inflammation and oxidative stress play
a central role in the pathogenesis of atherosclerosis at all
stages of severity of the disease.34,63 The cell types involved
in the atherosclerotic process include vascular endothelial
and smooth muscle cells, T-, B-, and NK T-lymphocytes,
monocytes/macrophages, and dendritic cells.64
Injury and subsequent activation of vascular endothe-
lium are considered to be the primer events in atherogen-
esis.65 Once activated, vascular endothelium produces IL-1,
IL-6 and other cytokines, and expresses several surface
adhesion molecules, such as intercellular adhesion
molecule-1, vascular cell adhesion molecule-1, and E- and
P-selectin, making it possible for leukocytes to adhere to
the damaged endothelial surface.65,66 Conversely, under
normal physiologic conditions, namely in the absence of
external insults, the human endothelium does not usually
permit adhesion of leukocytes, which are known to be the
building blocks of the arterial plaque genesis.
The expression of adhesion molecules and chemokines
by endothelial cells initially facilitates the recruitment of
macrophages. These express on their surfaces the so-called
scavenger receptors, which enable them to take up circu-
lating lipids, and become foam cells.65 Plaque formation is
accomplished by the activation and proliferation of
vascular smooth muscle cells, which migrate from the
arterial media into the intima, and produce an extracellular
matrix, whose accumulation in the plaque determines the
formation of fibro-fatty lesions.65,66
Endothelial dysfunction, accumulation of inflammatory
cells and lipids, and secretion of pro-inflammatory cytokines
by macrophages and other cells characterize the early pla-
que, and constitute a chronic pro-atherogenic environment.
In this context, CRP seems to contribute significantly to
aggravation of arterial lesions in that, as indicated by somestudies,67,68 it interacts with endothelial cells, stimulating
them to produce IL-6 and endothelin-1. Moreover, CRP up-
regulates the production of adhesion molecules, monocyte
chemotactic protein-1, and other inflammatory cytokines,
activates the complement system, promotes the uptake of
low-density lipoprotein (LDL) cholesterol by macrophages
and fosters the leukocyte adhesion to the vascular endo-
thelium, so amplifying the inflammatory cascade.67,68
Thus, CRP should be considered not only as a marker of
inflammation, but also as a pathogenetic factor in athero-
sclerosis. Bearing this in mind, it is not surprising that CRP
serum level has been reported in a number of studies as
a strong, independent predictor of cardiovascular morbidity
and mortality.68 For example, in the Framingham Study,
CRP levels of <1, 1e3, and >3 mg/L corresponded to low,
moderate, and high-risk patient-groups for cardiovascular
events, respectively.69
Myeloperoxidase is an enzyme secreted from activated
neutrophils, monocytes, and macrophages, which has
emerged as a potential contributing factor in the induction
and/or propagation of atherosclerosis.70 It generates
a number of ROS and diffusible radical species, that are
capable of both initiating lipid peroxidation71 and promoting
an array of post-translational modifications of target
proteins.72,73 Myeloperoxidase has also been implicated in the
in vivoenzymatic oxidation of low-density lipoproteins,which
potentiates the lipoprotein uptake from macrophages, with
increased cholesterol deposition and foam cell formation.71
Cigarette smoking represents one of the most relevant
risk factors for atherosclerosis, as well as for COPD. In fact, it
has been demonstrated that smokers are at significantly
higher risk of developing severe early atherosclerosis.
However, the pro-atherogenic effect of cigarette smoke
shortly reverses after cessation of smoking, and in quitters
the risk rapidly reaches that of nonsmokers, unless, as shown
by Kiechl and colleagues, they present clinical or serological
evidence of chronic airway infection.74 With this regard
a number of infectious agents have been implicated in the
atherogenesis. Sero-epidemiological studies have suggested
that several microorganisms, such as Chlamydia pneumonia,
Helicobacter pylori, cytomegalovirus, herpes simplex
virus1, and hepatitis A virus could all be considered as risk
factors for atherosclerosis.75e79 Moreover, prospective
studies have indicated an increased risk for cardiovascular
events in patients with serological evidence of prior infec-
tion, particularly in cases of multiple infections.80
Also some animal studies suggest a role for infection in
atherogenesis. Indeed, observations in mice indicate that
repeated, short-lasting infectious insults could cause
endothelial dysfunction and arterial damage, thus contrib-
uting to atherosclerosis progression.81,82
Since direct evidence relating a specific infectious agent
to atherogenesis is lacking at the moment, the current view
is that probably no single pathogen or single infectious
episode accounts for a multifactorial disease such as
atherosclerosis.75
In this regard, it has recently been suggested that it is
the “infectious burden”,83,84 rather than any specific
pathogen, that determines the infection-related propensity
to develop atherosclerosis. In this context, individuals
exposed to numerous infections throughout the life span
would be the most likely to develop atherosclerosis. Of
Table 1 Microbial pathogens isolated in COPD.
Bacteria
Haemophilus influenzae
Streptococcus pneumoniae
Moraxella catarrhalis
Pseudomonas aeruginosa
Enterobacteriaceae
Haemophilus haemolitycus
Haemophilus parainfluenzae
Staphylococcus aureus
Neisseria spp
Atypical bacteria
Chlamydophila pneumoniae
Mycoplasma pneumoniae
Cardiovascular events in COPD 919note, the infectious burden seems to be related to the
serum CRP level.85,86
A number of mechanisms, in conjunction with other
cardiovascular risk factors, have been advocated to explain
the role of infections in atherosclerosis.76
In vitro and in vivo epidemiological data suggest that
infectious agents have the potential to produce a pro-
inflammatory, pro-coagulant and pro-atherogenetic envi-
ronment in the vessel wall.87
Moreover, infections could contribute to atherogenesis
through their effects on lipid metabolism. Indeed, during
both acute and chronic infections a marked decrease may
occur in the levels of high-density lipoproteins, which
possess several important anti-atherogenic properties.
Another mechanism by which infections could exert
a pro-atherogenic action may be the induction of molecular
mimicry-based autoimmunity responses.88 For example,
heat shock proteins, which are a family of highly across-
species-conserved proteins, may be overexpressed due to
infectious agents, and act as “cryptic antigens”.75,89 The
immune response evoked by a pathogen might, therefore,
be addressed to a self antigen, represented by arterial heat
shock proteins, so inducing an autoimmune reaction that
may aggravate the atherosclerotic process.75Airway bacterial colonization, exacerbation
frequency, and systemic inflammation in COPD
The average frequency of COPD exacerbations is 1e2
annually, with a progressive increase as the severity of
disease increases.20 As indicated from clinical studies, the
exacerbation frequency has a significant influence on the
natural history of COPD, with amajor negative impact on the
patient’s well-being, hospital admission, and decline in lung
function.16,17,19 A subpopulation of COPD patients has
recently been identified that is particularly prone to develop
exacerbations, and seems to represent a distinct phenotype
of the disease characterized by frequent exacerbations.90
Several lines of evidence indicate bacteria as the
aetiological agents in up to 50% of COPD exacerbations.20
Until recently, a bacterial exacerbation was considered as
the result of an increased concentration (bacterial load) of
the same bacteria that chronically colonize the lower
airways of patients with stable COPD.20,91 Other observa-
tions, however, suggest that an additional role in the
pathogenesis of COPD exacerbation may be played by
acquisition of a new bacterial strain.91,92
In bronchoscopy studies, the prevalence of airway
colonization has been found to be about 25% and 50% in
stable and exacerbated COPD, respectively.93
It is generally assumed that airway bacterial coloniza-
tion in COPD during a phase of stability of the disease is
probably the result of a balance in which impaired host
defences are able to limit the number of bacteria but not
eradicate them,25 with cigarette smoking and severe airway
obstruction representing two additional risk factors for
colonization.94
The bacteria that most frequently colonize the lower
airways of COPD patients (Table 1) include Haemophilus
influenzae, Streptococcus pneumoniae, Moraxella catar-
rhalis, and Pseudomonas aeruginosa,21,23 whereas gram-negative Enterobacteriaceae, Staphylococcus aureus,
Haemophilu sparainfluenzae, and Haemophilus haemoliti-
cus are less frequently found.95
In the respiratory tract, the first-line antimicrobial
defence is represented by the barrier function of epithelia,
the mucociliary system, some antimicrobial peptides, such
as lisozyme, and the surfactant proteins, which are all
constitutively expressed.96,97 The second- and third-line
defence is provided by the innate and adaptive immune
response, respectively, both of which depend on the
recognition of pathogens by means of particular “pattern-
recognition receptors”.97 Among these, the Toll-like
receptors (TLR) are the best characterized, and seem to
play a key role in the host protection against microbes, by
activating multiple signalling pathways.17 The expression of
TLR-2 and TLR-4 on alveolar macrophages has been found
to be significantly reduced in stable COPD patients and
healthy smokers,98 suggesting some depression of the
innate immune response in these subjects.
A number of studies have shown that airway inflamma-
tion in COPD, both in the stable state and during exacer-
bations, is related to airway colonization.24,99,100 Indeed,
sputum levels of cytokines and chemokines, such as tumor
necrosis factor a, IL-8, and leukotriene B4, as well as
sputum levels of neutrophil products, such as myeloperox-
idase and neutrophil elastase, are increased in COPD
patients with airway colonization, as compared to patients
whose airways are not colonized.20,100,101 Similar results
have been obtained from bronchoalveolar lavage studies.22
While the association between airway bacterial coloni-
zation and airway inflammation is well established, the
relationship between bacterial colonization of the airways
and systemic inflammatory response in COPD in the stable
state has not been adequately explored and merits further
investigation.
It has, however, been observed that COPD exacerbations
are associated with a significant increase in both airway and
systemic inflammation,27,29 and that the degree of systemic
inflammation during exacerbations parallels the degree of
lower airway inflammation.29
In comparison to non-bacterial exacerbations, COPD
exacerbations sustained by bacteria, especially if they are
due to acquisition of a new bacterial strain, are associated
with an increased level of both airway and systemic
inflammation.25,101
920 S. Fuschillo et al.COPD patients with frequent exacerbations present,
during the stable state of the disease, increased total cell
and neutrophil counts, as well as increased IL-6, IL-8, and
tumor necrosis factor-a levels in the induced sputum, in
comparison to patients with less frequent exacerbations.24
Moreover, it has been demonstrated that frequent exacer-
bators show a reduced response to therapy, whichmay result
in persistently higher systemic inflammatory markers. This
could, at least in part, explain both the shorter interval until
the next exacerbation, as well as the accelerated decline in
lung function observed in these patients.15
There is now evidence that COPD exacerbations do not
always recover to baseline in regard to symptoms and lung
function.102 It may be that, as airway inflammatory markers
are increased during exacerbations, airway inflammation
perpetuates, leading to a progressive decline in lung
function.Conclusive remarks and future research
prospects
As discussed above, both COPD and atherosclerosis are
chronic, progressive, frequently coexisting disorders, that
share several risk factors and recognize commonSmok
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The increased prevalence of cardiovascular complica-
tions in non-respiratory chronic inflammatory diseases,
such as rheumatoid arthritis,103 suggests that also in COPD
inflammation could represent the pathophysiological
mechanism underlying the high cardiovascular morbidity
and mortality observed.
In this regard, it is now recognized that in COPD systemic
as well as airway inflammation, both in the stable state and
during exacerbations, are increased in patients with
frequent exacerbations, as compared to patients with
fewer exacerbations. On the other hand, it is also
acknowledged that frequent exacerbations are more likely
to occur in patients with airway bacterial colonization.
Similarly to COPD, the inflammation of atherosclerosis is
characterized by a chronic course, with intermittent periods
of acute exacerbations. The greater systemic inflammation
present in the stable state of COPD subjects with airway
colonization could contribute to the inflammatory process
underlying atherosclerosis. In addition, the peaks of
inflammatory activity accompanying COPD exacerbations,
especially if caused by infectious agents, could precipitate
acute exacerbations of the atherosclerotic process, with
increased risk of plaque rupture and thrombotic occlusion.ing
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Cardiovascular events in COPD 921In conclusion, COPD is associated with an increased
burden of atherosclerotic disease, and compelling evidence
suggests that systemic inflammation and oxidative stress
may play key roles in this association. Given that COPD
patients with airway bacterial colonization generally expe-
rience more frequent episodes of disease exacerbation and
present higher levels of both airway and systemic inflam-
mation compared to those without airway colonization, this
group should be considered at particularly increased risk of
developing cardiovascular complications (Fig. 2).
Also considering that up to 35%e45% of the total cost
absorbed by patients with COPD is spent in management of
acute exacerbations,104 preventive treatments specifically
addressed to patients with frequent exacerbations are
urgently needed. In this context, it would be particularly
desirable to design treatments capable of abolishing or, at
least, reducing airway bacterial colonization.
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